Saturday, July 11, 2026

Patent intelligence · US

US 10561606

Injectable long-acting local anesthetic semi-solid gel formulations

granted A61KA61K31/445A61K31/5575A61K31/56
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 14
Applicant portfolio 308
Patent details — US 10561606
Jurisdiction
US
Status
granted
Grant date
Feb 18, 2020
Expiration
Feb 13, 2040
Claims
20
CPC classes
A61K, A61K31/445, A61K31/5575, A61K31/56
View on Google Patents ↗

Quick answer

US 10561606 (Injectable long-acting local anesthetic semi-solid gel formulations) is held by MIRA PHARMA CORPORATION. Status: granted. Granted Feb 18, 2020. Expires Feb 13, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61K, A61K31/445, A61K31/5575, A61K31/56, A61K31/573, A61K45/06

More from MIRA PHARMA CORPORATION

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 10561606?

US 10561606 (Injectable long-acting local anesthetic semi-solid gel formulations) is held by MIRA PHARMA CORPORATION. Status: granted. Granted Feb 18, 2020. Expires Feb 13, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10561606?

MIRA PHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 10561606 expire?

Our index shows an expiration date of Feb 13, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.